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Abstract
Background: The increasing evidence associating general anaesthe-
tics with neurotoxicity and post-operative cognitive disturbances, 
mainly with deeper levels of anaesthetics, has led to more frequent 
use of adjuvants. This study aimed to analyse the effect of clonidine 
on the target dose of propofol in total intravenous anaesthesia.
Methods: A randomised, double-blind clinical trial was performed 
in a large hospital located in the southern region of Ceará, Brazil. 
Fifty-one patients from the anaesthesia outpatient clinic were en-
rolled. Patients were divided into two groups: one group received 
100 mL of 0.9% sterile saline, and the other group received 100 
mL of 0.9% sterile saline with clonidine at a dose of 3 µg/kg. A 
target-controlled infusion pump was used to administer propofol, 
following the modified Marsh pharmacokinetic model and aiming for 
a bispectral index (BIS) score of approximately 40 for intubation and 
45 for anaesthesia maintenance. The anaesthesiologist was informed 
which group the patient belonged to after completion of surgery 
and data recording.
Results: The chi-squared test was used to evaluate the distribution 
of the samples with respect to gender, and the Student’s t-test was 
used to evaluate the parametric variables. There was no statistically 
significant difference between the samples. A significant differen-
ce was observed in the target dose of propofol between the two 
groups during the maintenance and awakening phases, but not at 
the time of intubation.
Conclusions: Clonidine pre-operatively administered at a dose of 
3 µg/kg significantly reduced the target dose of propofol needed to 
maintain adequate levels of anaesthesia as measured by BIS.
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Background
Adjuvants have been used since the advent of 
anaesthetic use, and are gaining increasing impor-
tance in modern anaesthesia. General anaesthesia 
encompasses various states (hypnosis, pain elimina-
tion, inhibition of automatic reflexes, and muscular 
relaxation) which are impossible to achieve with a 
single drug. Atropine was administered prophylacti-
cally with the first inhalant anaesthetic (chloroform) 
to attenuate chloroform’s hypersialosis effect. [1] 
Although the mechanisms of action of general 
anaesthetics are still not completely understood, it is 
known that they act in various locations, with each 
medication acting in one specific location, [2] Cu-
rrently, the most accepted theory is that anaesthe-
tics act by stimulating [1] GABAA receptors, which 
inhibits NMDA receptors and blocks excitation at 
the cortical level. [2]
Evidence suggests that some anaesthetic drugs 
have a neurotoxic effect that continues beyond 
the exposure time, altering genes and protein ex-
pression. [3] Harmful effects have been recorded 
following exposure to ketamine, midazolam, pro-
pofol, isoflurane, sevoflurane, and desflurane. [3, 
5] Cognitive disturbances are common, mainly in 
elderly patients. [4]
It is unknown whether this neurotoxic effect is 
related to the drug used, the dose of anaesthetic, 
or the depth of the anaesthesia, or whether it de-
rives from characteristics that are inherent to the 
patient. However, promising strategies attribute a 
neuroprotective effect to lithium, melatonin, xenon, 
and alpha -2 (α2)–agonists. [3, 5] 
Adjuvants act in an additive or synergistic man-
ner with anaesthetics, facilitating the use of lower 
anaesthetic doses and minimizing their collateral 
effects. Adjuvants act in different, atypical locations. 
The majority of hypnotics produce their effects by 
connecting to the inhibitory gamma-aminobutyric 
acid A (GABAA) receptor, stimulating it or blocking 
the excitatory effect of the N-methyl-D-aspartate 
(NMDA) receptor. [2] Alpha-2 agonists, of which 
clonidine was the first to be approved for use in 
humans, act on the descending noradrenergic path 
to modulate pain, as well as on the 2 locus coeru-
leus, where they have a sedative effect. When used 
in association with general anaesthesia, clonidine 
permits the use of lower hypnotic doses, and some 
studies have shown an enhanced pain-modulating 
effect when it is administered in the intrathecal spa-
ce. [6] 
Clonidine is an adjuvant with an anxiolytic effect 
similar to that produced by the benzodiazepines, 
[7] and it has been used to treat panic disorders. 
[8] It can, however, produce an anxiogenic effect 
in larger doses.
When used immediately before surgery, and soon 
after induction of anaesthesia, it has a pain-modu-
lating and sedative effect and provides greater he-
modynamic stability, effects that continue postope-
ratively. Clonidine reduces the doses of halogenated 
anaesthetics when it is adjusted by hemodynamic 
response. [9]
Various studies have reported on the use of clo-
nidine as a pre-anaesthetic medication and have 
shown its effects on hemodynamic stability, post-
operative pain, hypnosis-sparing, and nausea and 
vomiting reduction. [10-13] This study aimed to 
analyse the effect of clonidine on the target dose 
of propofol in total intravenous anaesthesia.
Methods
The current study were approved by the 
ethical committe of platform Brazil (CAAE 
14626613.0.00000.0082), following the laws of the 
declaration of Helsincki. All patients received infor-
mation and signed an informed consent.
A randomised, double-blind clinical trial was per-
formed in a large hospital located in a municipali-
ty in the southern region of Ceará, Brazil. Patients 
undergoing laparoscopic cholecystectomy and oral 
and maxillofacial surgery were enrolled.
Sixty-five patients in the outpatient anaesthesia 
clinic were identified as potential candidates. After 
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applying inclusion criteria (>15 and <70 years of age, 
physical state P [American Society of Anesthesiolo-
gists, ASA] I-II, body mass index [BMI] below 35) 
and exclusion criteria (patients chronically taking 
benzodiazepines, barbiturates or opioid analgesics, 
drug addicts, patients with psychiatric disorders), 51 
patients remained. 
The patients were randomly assigned to either 
the clonidine or placebo group using a simple pro-
cess of drawing names from envelopes. Twenty-six 
patients received clonidine and 25 received a saline 
solution. 
Clonidine was prepared in 100 mL of 0.9% ste-
rile saline (SS) at a dose of 3 µg/kg, at the surgical 
centre's pharmacy by the responsible pharmacist. 
The identification on the saline solution only in-
cluded the patient’s name. The group selected to 
receive the placebo received 100 mL of 0.9% SS 
without any additive, which was also dispensed by 
the surgical centre's pharmacy. One anaesthesiolo-
gist participated in the double-blind study; neither 
patients, nor the anaesthesiologist knew the iden-
tities of the groups.
All the patients received standard monitoring, 
which involved pulse oximetry, cardiography, 
non-invasive blood pressure measurement, cap-
nography following orotracheal intubation, and 
assessment of temperature and hypnosis, using 
a unilateral 3BIS VISTA Aspect® monitor. The 
standard solution of 100 mL of 0.9% SS recei-
ved from the pharmacy was administered intra-
venously over 10 min. Ten minutes after the end 
of the infusion, anaesthesia was induced with 
a fentanyl bolus at a dose of 3 µg/kg. Next, 
propofol fresenius® was administered through 
a target-controlled infusion pump (Base Primea 
Fresenius®), using the modified Marsh model. 
The initial programmed target dose was 4 µg/mL, 
adjusted to reach a BIS (bispectral index) score of 
40. Remifentanil was initiated at a dose of 0.30 
µg/kg/min, followed by 1 mg/kg of lidocaine and 
0.15 mg/kg of cisatracurium.
Anaesthesia was maintained with propofol and 
remifentanil, aiming for a BIS score of approxima-
tely 45, and the target dose of propofol was recor-
ded again at 30 minutes. At the conclusion of the 
procedure, the propofol pump was turned off, the 
remifentanil infusion was reduced to 0.05 µg/kg/
min and the team waited for the patient to spon-
taneously awaken.
All patients received 4 mg ondansetron and 8 
mg dexamethasone as prophylaxis for nausea and 
vomiting. An analgesic with a local anaesthetic was 
applied to the incision and 30 mg/kg dipyrone and 
1.5 mg/kg ketoprofen were administered systemica-
lly, except in cases of reported allergy. 
All patients were aroused with 1 mg of atropi-
ne and 50 mg/kg of neostigmine. Two patients re-
quired a supplemental dose of 0.5 mg of atropine 
due to severe bradycardia (<40 bpm), and recovered 
without further complications. Patients were sent 
to the post-anaesthetics recovery room and were 
discharged 3 to 4 h later, after having reached an 
Aldrete-Kroulik score of 9.
Results
The statistical analysis of group homogeneity with 
respect to the non-parametric distribution of varia-
bles was performed using the x2 test, with a Ya-
tes correction, yielding x2=0.024 with 1 degree of 
freedom and p = 0.8772, showing that there was 
no statistically significant difference between the 
samples (Table 1). 
Table 1.  Distribution by gender of placebo and clo-
nidine groups 
Gender Clonidine Placebo Total
Male 14 14 28
Female 12 11 23
Total 26 25 51
The x2 test, with Yates correction, yielded x2=0.024 with 1 
degree of freedom and p = 0.8772, showing that there was 
no statistically significant difference in the distribution of 
gender between the groups.
InternatIonal archIves of MedIcIne
Section: AneStheSiology & emergency medicine
Issn: 1755-7682 
2015
Vol. 8 No. 45
doi: 10.3823/1644
This article is available at: www.intarchmed.com and www.medbrary.com 4
The Student’s t-test was used to evaluate the 
differences in means with respect to age, weight, 
height, and the mean target doses of propofol. 
There was no statistically significant difference bet-
ween the samples with respect to age, weight, 
or height (Tables 2 and 3). However, a significant 
difference in the target dose of propofol was ob-
served between the 2 groups in the maintenance 
and awakening phases, but not at the time of in-
tubation (Table 4).
The most significant difference occurred at 30 
min, where a p < 0.0001 was calculated with a 
Table 4. Target dose of propofol at three time points in surgery patients 
Time Clonidine Placebo BIS p
Intubation 3.923 ± 0.592 4.2 ± 0.464 40 ± 4.3 0.0697
30 min 1.5 ± 0.377 3.2 ± 0.627 45 ± 3.6 <0.0001
Awakening 0.588 ± 0.19 0.976 ± 0.268 90 ± 6 <0.0001
Table 2.  Demographic distribution of the clonidine 
group.
Gender Age Weight Height BMI
M 50 72 1.72 24.34
M 25 74 1.73 24.73
M 37 81 1.71 27.70
M 16 49 1.72 16.66
M 27 60 1.65 22.04
M 19 65 1.70 22.49
M 39 62 1.80 19.14
M 59 62 1.60 24.22
M 15 53 1.64 19.71
M 23 54 1.62 20.58
F 54 40 1.49 18.02
F 19 56 1.54 23.61
F 41 62 1.55 25.81
F 66 56 1.51 24.56
F 38 55 1.55 22.89
M 24 70 1.75 22.86
F 43 63 1.53 26.91
F 58 75 1.55 31.22
F 20 57 1.60 22.20
M 21 67 1.68 23.74
F 22 62 1.76 20.02
M 16 60 1.67 21.51
F 63 72 1.52 31.16
F 52 67 1.54 28.25
M 18 68 1.70 23.53
F 42 57 1.65 20.94
Mean 
and SD
34.88 ± 16.55 62.27±8.96 1.62±0.09 23.42±3.61
M= male; F = female; BMI = body mass index; 
SD = standard deviation  
Table 3. Demographic distribution of saline group.
Gender Age Weight Height BMI
F 48 65 1.65 23.88
M 17 75 1.74 24.77
M 36 67 1.68 23.74
M 25 75 1.73 25.06
M 22 67 1.72 22.68
F 35 60 1.56 24.65
M 56 65 1.68 23.03
F 36 63 1.59 24.92
F 26 62 1.62 23.62
F 40 80 1.68 28.34
M 37 59 1.72 19.94
F 16 50 1.56 20.55
F 43 45 1.52 19.48
M 26 71 1.83 21.20
M 39 62 1.63 23.34
M 33 73 1.7 25.26
M 17 63 1.71 21.55
M 24 65 1.7 22.49
M 29 57 1.7 19.72
F 25 69 1.62 26.29
F 64 40 1.44 19.29
M 19 79 1.81 24.11
F 25 83 1.58 33.25
M 19 67 1.71 22.91
F 34 69 1.52 29.86
Mean 
and SD
31.64 ± .24 65.24 ± .18 1.65 ± .097 23.57 ± 3.27
M = male; F = female; BMI = body mass index; 
SD = standard deviation
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difference between the groups’ means of 1.7 at a 
confidence interval of 95% (1.44-1.99). A t value 
of 11.7828 with 49 degrees of freedom was found.
The two groups were similar with respect to gen-
der, weight, height, and age. There was no signifi-
cant difference in the target dose of propofol at the 
time of intubation: the mean value for the clonidine 
and placebo groups was 3.92 µg/mL and 4.2 µg/
mL, respectively. Thirty minutes after the beginning 
of surgery, a statistically significant difference was 
observed: the mean target dose of propofol was 
1.5 µg/mL in the clonidine groups and 3.2 µg/mL in 
the placebo group (p < 0.0001) (Tables 5 and 6). A 
statistically significant difference was also observed 
at the time of awakening: the mean target dose of 
propofol was 0.59 µg /mL in the clonidine group 
and 0.98 µg/mL in the placebo group. (Figure 1) 
Target dose of propofol at intubation, 30 min and 
at awakening in clonidine and placebo groups (fi-
gure 2).
Table 5.  Target dose of propofol at three time 







M 4.0 1.3 1.3 0.3
M 3.5 2.3 2.3 0.7
M 4.0 1.8 1.8 0.6
M 3.0 1.2 1.2 0.4
M 5.0 1.5 1.5 0.5
M 5.0 2.2 2.2 1.1
M 4.0 1.2 1.2 0.4
M 3.5 2.3 2.3 0.4
M 4.0 1.5 1.5 0.6
M 4.5 1.8 1.8 0.9
F 2.0 0.4 0.4 0.2
F 4.0 1.5 1.5 0.5
F 4.5 1.6 1.6 0.6
F 3.5 1.4 1.4 0.4
F 3.6 1.5 1.5 0.6
M 4.0 1.5 1.5 0.7
F 4.5 1.4 1.4 0.6
F 4.0 1.5 1.5 0.7
F 4.0 1.5 1.5 0.6
M 3.5 1.3 1.3 0.5
F 4.0 1.3 1.3 0.6
M 4.0 1.4 1.4 0.8
F 3.9 1.4 1.4 0.6
F 4.0 1.5 1.5 0.7
M 4.0 1.4 1.4 0.8
F 4.0 1.3 1.3 0.5
Mean 
and SD
3.92 ± 0.59 1.5 ± 0.38 1.5 ± 0.38 0.59 ± 0.19
M = male; F = female; OTI = orotracheal intubation;
SD = standard deviation
Table 6.  Target dose of propofol at three time 







F 4.0 3.4 1.65 1.2
M 4.5 3.7 1.74 1.2
M 4.0 3.4 1.68 1.3
M 4.0 3.2 1.73 0.9
M 4.0 3.5 1.72 1.0
F 3.9 3.2 1.56 0.9
M 3.7 3.0 1.68 0.7
F 4.0 3.0 1.59 0.9
F 4.0 3.0 1.62 0.9
F 4.0 3.2 1.68 0.8
M 5.0 4.0 1.72 1.0
F 4.5 3.5 1.56 1.0
F 4.5 3.5 1.52 1.0
M 4.0 3.0 1.83 0.9
M 4.9 2.8 1.63 0.7
M 4.5 4.2 1.7 1.5
M 4.0 4.0 1.71 0.8
M 5.0 3.0 1.7 0.9
M 5.0 3.8 1.7 1.3
F 4.0 1.6 1.62 0.7
F 3.0 1.4 1.44 0.3
M 4.5 3.2 1.81 0.7
F 4.0 3.0 1.58 1.4
M 4.0 3.2 1.71 1.2




4.2 ± 0.46 3.2±0.63 1.65 ± .097 0.97±0.27
M = male; F = female; OTI = orotracheal intubation; 
SD = standard deviation
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Discussion
In this study, 16 patients undergoing laparoscopic 
cholecystectomy and 35 patients undergoing oral 
and maxillofacial surgery received total intravenous 
anaesthesia using propofol and remifentanil. The 
effect of clonidine was evaluated as a pre-medi-
cation in the target dose of propofol, during total 
intravenous anaesthesia with propofol and remifen-
tanil using a target-controlled infusion pump and a 
modified Marsh model [30].
The effects of clonidine as a sedative, anxiolytic, 
analgesic, anti-emetic, in addition to the preven-
tion of post-operative tremors [11] and maintenan-
ce of cardiovascular stability, [12, 16] are known 
and have been shown in various studies. Unlike 
other classes of sedatives, clonidine has the uni-
que feature of causing minimal or no respiratory 
depression. [17]
Clonidine’s analgesic effects are difficult to eva-
luate perioperatively, due to a lack of specific devi-
ces that can evaluate pain. However, its synergism 
with propofol can be shown by BIS [22, 33]. Cloni-
dine used alone has a sedative effect, which in iso-
lation alters the BIS values and the analgesic effect. 
However, it does not have sufficient hypnotic and 
analgesic effects to provide anaesthesia, even when 
administered by the intrathecal route. [25, 28, 29] 
There was no difference in the target doses of 
propofol at the time of induction, probably because 
the location where clonidine's action has a sedative 
effect is in the locus coeruleus, and it is necessary to 
cross the blood-brain barrier to occupy its receptors 
and reach its maximum effect. Another study found 
a reduction in the induction dose of propofol, but 
no effect on the maintenance dose. Therefore, the 
infusion was based on hemodynamic variables to 
guide the depth of the anaesthesia, which is not 
ideal, especially with the use of drugs that dull the 
automatic response, like α2-agonists. [14]
Various drugs have been compared with clonidine 
as pre-anaesthetic medications, mainly benzodiaze-
pines such as midazolam [7] and diazepam, which 
show greater post-operative agitation. [10-12] Ga-
bapentin did not show superiority in post-operative 
pain relief. Ketamine showed better post-operati-
ve pain relief, but also had a greater incidence of 
agitation and hypersalivation, [21] and magnesium 
sulphate showed no benefits with respect to cloni-
dine. [22] All of the studies showed similar effects 
with respect to sedation level and patient satisfac-
tion; however, only clonidine showed synergism 
with opioids and hypnotics [31, 32].
There are studies describing the perineural ad-
ministration of clonidine to prevent chronic pain, 
Figure 1: Flowchart. Figure 2:  Target dose of propofol at intubation, 
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especially in situations where there are large nerve 
injuries, such as limb amputations. The probable 
mechanism is a decrease in production of pro-in-
flammatory cytokines, mainly IL1ß and TNFα. [23] 
Animal research has shown that clonidine adminis-
tration before hypoxia improves endothelial function 
and modulates the inflammatory response during 
reperfusion. [24] 
Systematic reviews performed in 2009 by the Co-
chrane Collaboration (revised again in 2013) con-
cluded that α2-agonists reduce cardiac risk, mainly 
in vascular surgery. Therefore, it is suggested that 
more studies will be necessary to confirm its be-
nefits and safety to use in conjunction with other 
perioperative interventions like ß-blockers. [26] 
Recently, a randomised, double-blind, multi-cen-
tre clinical trial with a sample of 10,010 patients 
from 135 hospitals distributed across 23 countries 
was performed, evaluating the effect of clonidine, 
placebo, and ASA status. The clonidine group recei-
ved 200 µg orally 2 to 4 hours before the surgical 
procedure, and as a transdermal patch that released 
200 µg/24 h of clonidine, which was replaced every 
72 hours post-surgery. Patients were monitored for 
30 days. The primary outcome evaluated was death 
or non-fatal myocardial infarction. This study con-
cluded that low doses of clonidine (200 µg orally + 
200 µg/24 h transdermally) did not reduce mortality 
or non-fatal myocardial infarction. However, it did 
elevate the risk of hypotension, bradycardia, and 
non-fatal heart attacks. 
The result of this study raised questions as to the 
real benefits of clonidine in a perioperative scenario 
and the ideal dose adjustment by age group. The 
mean age of the patients in this study was 68.6 
years. The patients were diverse, with many taking 
various medications, and the type of anaesthesia 
administered was not specified in detail in addition 
to the large number of co-morbid conditions in the 
study. However, the sample was extremely signifi-
cant. [27] Similarly, there are still controversies with 
respect to the adequate dose in intrathecal use of 
clonidine, with various studies recommending doses 
of 15 to 450 µg. The majority suggest adjusting 
the dose by factors such as age, time in surgery, 
presence of co-morbid conditions, and the dose of 
local anaesthetics and opioids used. [28, 35]
Conclusions
Clonidine, administered at a dose of 3 µg/kg through 
intravenous infusion over 10 minutes and 10 minutes 
before anaesthetic induction significantly decreased 
the target doses of propofol at 30 min during sur-
gery and the target dose on awakening. However, it 
did not reduce the doses of propofol in anaesthetic 
induction.
The sedative effects of clonidine act synergistica-
lly with the hypnotic effects of propofol, permitting 
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